Baker McKenzie Baker McKenzie
How Can We Help?
  • Home
  • Expertise
  • Healthcare & Life Sciences
Language:
English

Healthcare & Life Sciences

blue and violet wire-shaped patterns against a blue background
Insight | Topic

Healthcare & Life Sciences Hub

Stay apprised on key market trends, risks, opportunities and legal issues through our dedicated resources hub.
Read More

Healthcare and life sciences companies face immense opportunity and disruption. The increasing innovation in new product breakthroughs; interplay between drugs, devices and tech; cost pressures; and demand for patient centricity have created a melting pot for agility and change.

Businesses turn to Baker McKenzie to enter new markets, maximize operational efficiencies, build a long-term pipeline of innovative products and demonstrate efficacy. We provide commercial legal advice to help anticipate and manage new risk and avoid disconnect between global strategy and the law enabling your company to provide better care to patients across the globe.

Visit InsightPlus for our latest legal updates covering Healthcare & Life Sciences developments across the globe

Insight | Thought Leadership
Looking Ahead: Business Impact of a New US Administration
As Donald Trump prepares to take office as the 47th US president, we outline the policy positions we expect to see across five key areas that will have significant implications for business.
Insight | Handbook
Doing Business in the United Arab Emirates 2024
Comprehensive guide to understanding the current investment and legal landscape in the UAE.
Insight | Handbook
Ukrainian Laws in Wartime
Our guide provides an overview of the key features of wartime legislation.
Insight | Legal Update
UK General Election Manifesto and Policy Tracker
A summary of the policies outlined in the Conservative and Labour manifestos and an indication of what the potential impact on businesses and individuals may be.
Insight | Thought Leadership
Unlocking and Accelerating Growth: Healthcare and Life Sciences in Asia Pacific
Healthcare and life sciences breakthroughs offer opportunities to meet patient needs and create value, but rising costs and market uncertainty also apply significant pressure to operations.
Insight | Legal Update
WHO Releases AI Ethics and Governance Guidance for Large Multimodal Models
The WHO guidance summarizes the broad applications of LMMs in the healthcare industry, including recommendations for governments, and for public health and medical purposes.
Insight | Thought Leadership
The Year Ahead: Global Disputes Forecast 2024 Report
Our seventh annual report provides detailed analysis of disputes trends to prepare your organization for 2024.
Insight | Legal Update
Supporting clients to seize Korea’s substantial opportunities
Our lawyers discuss the abundant opportunities that Korea presents and how the JV supports clients with their Korea inbound and outbound investments and business expansion. 
Insight | Handbook
Guide to IPOs for Biotech and Pharma Companies
Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.
Insight | Legal Update
How Has 2023 Panned Out for the Life Sciences Industry in Asia Pacific?
Ben McLaughlin and Andrew Martin discuss key trends and developments in 2023.
Insight | Podcast
Talking M&A
From navigating the complexities of carve-outs or tech transactions to cross-border trends, gain expert insights and uncover key topics in a complex transactional landscape.
View All Insight
News
Deal Digest: Q3 2024
M&A, private equity and other complex transactions from across the globe
News | Deal Announcement
Baker McKenzie Client Lundbeck to Acquire Longboard in USD 2.6 Billion Transaction
The proposed acquisition represents a significant step forward in Lundbeck’s Focused Innovator strategy.
News | Firm News
Experienced AI and Healthcare Technology Lawyer Keo McKenzie Rejoins Baker McKenzie as a Partner in Washington, DC
With over a decade of experience in a range of regulatory and transactional issues, Keo focuses on those involving AI and digital health technologies.
News | Firm News
Baker McKenzie Continues Growth of Global M&A Practice with High-Calibre Team Hire in Singapore
Baker McKenzie Wong & Leow, the member firm of Baker McKenzie in Singapore, announces the upcoming addition of a team in Singapore, led by principals Shirin Tang and Ang Lip Kian. The team joins ...
News | Awards & Recognition
Baker McKenzie Secures Top Rankings in the 2024 Edition of "Ukrainian Law Firms: A Handbook for Foreign Clients"
The rankings highlight the Firm's leadership in complex transactional, corporate and regulatory matters across various industries.
News | Deal Announcement
Baker McKenzie Advises Baxter in USD 3.8 Billion Divestiture of Vantive Kidney Care Segment to Carlyle
The deal represents a key milestone in Baxter’s ongoing business transformation, enabling heightened strategic clarity, operational efficiency and innovation.
News | Press Coverage
Singapore taps Vietnam for M&A/ investment opportunities; healthcare, real estate and construction sectors are key focus
M&A partner Seck Yee Chung shares his views about the future outlook of Singapore M&A deals in Vietnam.
News | Press Coverage
Alan Zoccolillo speaks to Mergermarket / Ion Analytics about deal activity in the North America healthcare sector
Alan Zoccolillo, discussed with Mergermarket/Ion Analytics the current trends driving the market and the near-term outlook for M&A activity in the sector.
News | Deal Announcement
Baker McKenzie advises CureVac on restructuring collaboration with GSK into a new licensing agreement
The new licensing agreement will allow each company to prioritize investment and focus on their respective mRNA development activities.
News | Deal Announcement
Baker McKenzie advises Mitsubishi Tanabe Pharma on the sale of the European Argatroban business to Ethypharm
Baker McKenzie advised Mitsubishi Tanabe Pharma Corporation on the conclusion of an agreement with Ethypharm for the sale and transfer of the antithrombin drug Argatroban business in Europe.
News | Firm News
Baker McKenzie’s Global India Practice Committee welcomes three new members
Four committee members have also been named to India Business Law Journal’s “The International A-List” for 2024.
View All News
Events | Upcoming Webinar
Global Healthcare & Life Sciences Webinar Series
Our Global Healthcare & Life Sciences Webinar Series aims to share legal industry insights and provide practical guidance in the context of today's evolving world.
Events | Upcoming Webinar
Asia Pacific Competition Spotlight
Our new series explores sector-specific competition law and business challenges faced by legal counsel and business leaders in Asia Pacific.
Events | Event
Baker McKenzie at J.P. Morgan Healthcare Conference 2025
Connect with Baker McKenzie’s Healthcare & Life Sciences team on the week of J.P. Morgan Healthcare Conference 2025
View All Events

Ranked in the Top 4 Law Firms in the World for Life Sciences, Chambers Global

Americas

  • Ranked in Healthcare: Pharmaceutical/Medical Products Regulatory, Chambers USA 2024 (District of Columbia)
  • Band 1 for Life Sciences, Chambers Latin America 2024 (Mexico)
  • Band 2 for Life Sciences and Healthcare, Chambers Latin America 2024 (Peru)
  • Tier 1 for Life Sciences and Healthcare, Legal 500 Latin America 2024 (Argentina)
  • Tier 1 for Life Sciences, Legal 500 Latin America 2024 (Mexico)
  • Tier 2 for Life Sciences, Legal 500 Latin America 2024 (Colombia)
  • Impact Deal of the Year - Poseida Therapeutics/Takeda, LMG Life Sciences Americas 2022 (US)
  • Impact Deal of the Year - Pfizer/Trillium Therapeutics, LMG Life Sciences Americas 2022 (Canada)
  • FDA Regulatory Firm to Watch, LMG Life Sciences Awards 2020 (US)
  • Licensing and Collaborations Recommended Firm, LMG Life Sciences 2021 and 2020 (US)

Europe, Middle East and Africa

  • Band 1 for Life Sciences, Chambers Europe 2024 (Hungary)
  • Band 2 for Life Sciences, Chambers Europe 2024 (Germany and Spain)
  • Listed for Healthcare & Life Sciences (Industry Focus and Regulatory), Legal 500 EMEA 2024 (Germany)
  • Tier 2 for Healthcare & Life Sciences (Industry Focus), Legal 500 EMEA 2024 (France, Italy, Spain)
  • Tier 2 for Healthcare & Life Sciences (Industry Focus), Legal 500 UK 2024 (London)
  • Law Firm of the Year for Health and Research, Top Legal Industry Awards (Italy)
  • Regulatory Firm of the Year, LMG Life Sciences EMEA 2022 (Türkiye) - Esin Attorney Partnership (a Member Firm of Baker McKenzie International)
  • Türkiye Firm of the Year, LMG Life Sciences EMEA 2022 (Türkiye) - Esin Attorney Partnership (a Member Firm of Baker McKenzie International)
  • Impact Deal - Vifor Pharma/Sanifit, LMG Life Sciences EMEA 2022 (Türkiye) - Esin Attorney Partnership (a Member Firm of Baker McKenzie International)

Asia Pacific

  • Band 1 for Life Sciences (Asia Pacific Region), Chambers Global 2014 to 2024 Chambers Asia Pacific 2014 to 2024
  • Band 2 for Life Sciences, Chambers Asia Pacific 2024 (Australia)
  • Band 2 for Life Sciences (International Firms), Chambers Greater China Region 2024 (China)
  • Tier 2 for Healthcare and Life Sciences (Foreign Firms), Legal 500 Asia Pacific 2023 (China)

How We Can Help

Explore Healthcare & Life Sciences

About Us

Learn about our Global Healthcare & Life Sciences Industry Group in five minutes.


Healthtech and Biotech M&A

The healthcare tech and biotech industries shifted fundamentally during the pandemic. Enthusiasm for dealmaking continues to be a growth area.

>> 16-minute listen

Flares of different colored light against a black background

Guide to IPOs for Biotech and Pharma Companies

Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.


Global Healthcare & Life Sciences Webinar Series

Aims to share legal industry insights and provide practical guidance in the context of today's evolving world.


Key Contacts

*Trench Rossi Watanabe (Brazil) and Baker McKenzie have executed a strategic cooperation agreement to consult on foreign law.